Physician profile
Jeffrey E Pearce
NPI 1700971660
$539.45
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $255.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $51.61 | 2020 | |
| Upsher-Smith Laboratories LLC | $48.32 | 2020 | |
| Greenwich Biosciences, INC. | $42.86 | 2019 | |
| Emd Serono, INC. | $42.82 | 2020 | |
| Assertio Therapeutics, INC. | $41.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.87 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $32.86 | 2019 | |
| Lilly USA, LLC | $29.76 | 2019 | |
| Amgen INC. | $23.69 | 2020 | |
| Alfasigma USA, INC. | $23.51 | 2020 | |
| Pfizer INC. | $22.94 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $22.92 | 2019 | |
| Bausch Health US, LLC | $22.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.59 | 2019 | |
| Boston Scientific Corporation | $20.25 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $16.85 | 2019 | |
| Medtronic USA, INC. | $16.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.23 | 2019 | |
| Csl Behring | $11.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.